Trial reportInternational journal of geriatric psychiatry2011
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Trial report in International journal of geriatric psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00009217 (Treatment of Behavioral Symptoms in Alzheimer's Disease), which is not on this map. Cited by 25 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Behavioral Symptoms in Alzheimer's Disease
Who cites it
25 citing papers in PubMed, 7 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Pooled it
- A European Academy of Neurology guideline on medical management issues in dementia.European journal of neurology · 2020Guideline
- Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.Frontiers in aging neuroscience · 2019Pooled it
- Effects of discontinuation of chronic medication in primary care: a systematic review of deprescribing trials.The British journal of general practice : the journal of the Royal College of General Practitioners · 2018Pooled it
- Pharmacological interventions for apathy in Alzheimer's disease.The Cochrane database of systematic reviews · 2018Pooled it
- Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.Canadian family physician Medecin de famille canadien · 2018Guideline
- The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.British journal of clinical pharmacology · 2016Pooled it
- The Effects ofNutrients · 2022Trial
- Relapse risk after discontinuation of risperidone in Alzheimer's disease.The New England journal of medicine · 2012Trial
- Blood lactate levels in patients receiving first- or second- generation antipsychotics.Croatian medical journal · 2011Trial
- Drug repositioning with adaptive graph convolutional networks.Bioinformatics (Oxford, England) · 2024Article
- New approaches to symptomatic treatments for Alzheimer's disease.Molecular neurodegeneration · 2021Review
- Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation-Liaison Service.Current psychiatry reports · 2020Review
- Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia.The Cochrane database of systematic reviews · 2018Review
- Review
- Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms.European journal of clinical pharmacology · 2017Review
- Approaches to Gradual Dose Reduction of Chronic Off-Label Antipsychotics Used for Behavioral and Psychological Symptoms of Dementia.The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists · 2015Review
- Management of Behavioral and Psychological Symptoms of Dementia.Noro psikiyatri arsivi · 2014Review
- Medication monitoring for people with dementia in care homes: the feasibility and clinical impact of nurse-led monitoring.TheScientificWorldJournal · 2014Article
- Geriatric psychiatry review: differential diagnosis and treatment of the 3 D's - delirium, dementia, and depression.Current psychiatry reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveIn patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation.
methodsIn outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of haloperidol (0.5-5 mg daily) were randomized to a 24-week, double-blind pilot trial of discontinuation on placebo versus continuation haloperidol. Phase A response criteria were minimum 50% reduction in three target symptoms, and improvement on the Clinical Global Impression-Change (CGI-C) score for psychosis/agitation. Phase B relapse criteria required 50% worsening in target symptoms and on the CGI-C. α = 0.1 was the significance criterion in this pilot study.
resultsOf 44 patients, 22 patients responded in Phase A. The sum score of target symptoms, and Brief Psychiatric Rating Scale (BPRS) psychosis and hostile suspiciousness factor scores, decreased in Phase A (p's < 0.001). Extrapyramidal signs increased in Phase A (p < 0.01). Of 22 responders, 21 patients entered Phase B, and 20 had at least one follow-up visit. Four of 10 patients (40%) on continuation haloperidol relapsed compared to eight of 10 patients on placebo (80%, χ(2) = 3.3, p = 0.07). In survival analyses, time to relapse was shorter on placebo than haloperidol (χ(2) = 4.1, p = 0.04).
conclusionsHaloperidol open treatment was efficacious, and relapse was greater on placebo than with haloperidol continuation. In patients with AD who have psychosis or agitation and respond to antipsychotic medication, the increased risk of relapse after discontinuation needs to be weighed against the side effects associated with continuing the medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.